Evaluation of the Quantum Blue® rapid test for faecal calprotectin

Annals of Clinical Biochemistry

Volumn 49, Issue 1, 2012, Pages 55-58

  Wassell, Julie ^a   Wallage, Michael ^a   Brewer, Ella ^a  

^a NORTH BRISTOL NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALGRANULIN;

ARTICLE; CLINICAL ARTICLE; DIGESTIVE SYSTEM INFLAMMATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; FECES ANALYSIS; HUMAN; INTERMETHOD COMPARISON; POINT OF CARE TESTING; PRIORITY JOURNAL; PROTEIN ANALYSIS; QUANTUM CHEMISTRY;

ACUTE-PHASE PROTEINS; BIOLOGICAL MARKERS; CALIBRATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; HUMANS; INFLAMMATORY BOWEL DISEASES; LEUKOCYTE L1 ANTIGEN COMPLEX; POINT-OF-CARE SYSTEMS; SENSITIVITY AND SPECIFICITY;

EID: 84855979815     PISSN: 00045632     EISSN: 17581001     Source Type: Journal    
DOI: 10.1258/acb.2011.011106     Document Type: Article

References (17)

1. Meucci G, D'Incà R, Maieron R, et al. Diagnostic value of faecal calprotectin in unselected outpatients referred for colonoscopy: a multicenter prospective study. Dig Liver Dis 2010;42:191-5
2. Sutherland AD, Gearry RB, Frizelle FA. Review of fecal biomarkers in inflammatory bowel disease. Dis Colon Rectum 2008;51:1283-91
3. Gisbert JP, McNicholl AG. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis 2009;41:56-66
4. Schoepfer AM, Trummler M, Seeholzer P, Seibold-Schmid B, Seibold F. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis 2008;14:32-9
5. Centre for Evidence-based Purchasing. Value of Calprotectin in Screening outIirritable Bowel Syndrome: Evidence Review. London: NHS Purchasing and Supply Agency, 2009: CEP09026
6. Gerasimidis K, Nikolaou CK, Edwards CA, McGrogan P. Serial fecal calprotectin changes in children with Crohn's disease on treatment with exclusive enteral nutrition: associations with disease activity, treatment response, and prediction of a clinical relapse. J Clin Gastroenterol 2011;45:234-9
7. Kallel L, Ayadi I, Matri S, et al. Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study. Eur J Gastroenterol Hepatol 2010;22:340-5
8. Caccaro R, D'Incá R, Sturniolo GC. Clinical utility of calprotectin and lactoferrin as markers of inflammation in patients with inflammatory bowel disease. Expert Rev Clin Immunol 2010;6:551-8
9. Sipponen T, Björkesten CG, Färkkilä M, Nuutinen H, Savilahti E, Kolho KL. Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scand J Gastroenterol 2010;45:325-31
10. Wassell J, Dolwani S, Metzner M, Losty H, Hawthorne A. Faecal calprotectin: a new marker of Crohn's disease. Annals Clin Biochem 2004;14:230-2
11. Calprotectin ELISA Simplifies and efficient stool extraction using a faecal sample preparation kit. See http://buhlmannlabs.ch/files/documents/core/Inflammation/ek-cal/Corporate/psf001ml-03eweb.pdf. (last checked 9 May 2011)
12. Bühlmann Quantum Blue Calprotectin kit insert. LF-CAL20-RD. Revision date 2010-06-02. Switzerland: Bühlmann, 2010
13. van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010;341:c3369
14. Damms A, Bischoff SC. Validation and clinical significance of a new calprotectin rapid test for the diagnosis of gastrointestinal disease. Int J Colorectal Dis 2008;23:985-92
15. Vestergaard TA, Nielsen SL, Dahlerup JF, Hornung N. Fecal calprotectin: assessment of a rapid test. Scan J Clin Lab Invest 2008;68:343-7
16. Husebye E, Tǿn H, Johne B. Biological variability of fecal calprotectin in patients referred for colonoscopy without colonic inflammation or neoplasm. Am J Gastroenterol 2001;96:2683-7
17. Jellema P, van Tulder MW, van der Horst HE, Florie J, Mulder CJ, van der Windt DA. Inflammatory bowel disease: a systematic review on the value of diagnostic testing in primary care. Colorectal Dis 2011;13:239-54